我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

降钙素原（PCT）对急性冠脉综合征诊断的临床意义

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第2期
页码:
236-238
栏目:
综述
出版日期:
2014-01-20

文章信息/Info

Title:
Procalcitonin (PCT) in the diagnosis of acute coronary syndrome
作者:
何晓全; 范 琰; 刘梅林
(北京大学第一医院老年内科，北京 100031)
Author(s):
HE Xiao-quan;  FAN Yan;  LIU Mei-lin
(Department of Geriatrics, First Hospital, Beijing University, Beijing 100031, China)
关键词:
降钙素原; 冠状动脉疾病; 急性冠脉综合征; 诊断
Keywords:
coronary heart disease;  acute coronary syndrome;  diagnosis
分类号:
R543.3
DOI:
-
文献标识码:
A
摘要:
近年来，炎症反应标志物降钙素原（PCT）引起关注，本文对PCT及其在冠心病尤其对急性冠脉综合征诊断的研究进展进行综述。
Abstract:
The pathological changes of atherosclerosis represent an inflammatory response. Studies have shown that acute coronary syndrome (ACS) manifests acute inflammation. In recent years, procalcitonin (PCT), an inflammatory marker, has attracted much attention. This article mainly reviews the research progress of PCT in the diagnosis of coronary heart disease, especially ACS.

参考文献/References

[1]Businaro R,Tagliani A,Buttari B,et al.Cellular and molecular players in the atherosclerotic plaque progression[J].Anna N Y Acad Sci,2012,1262:134-141.
[2]Dekker MS,Mosterd A,van’t Hof AW,et al.Novel biochemical markers in suspected acute coronary syndrome: systematic review and critical appraisal[J].Heart,2010,96(13):1001-1010.
[3]Dellinger RP,Levy MM,Carlet JM,et al.Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008[J].Crit Care Med,2008,36(1):296-327.
[4]Schuetz P,Albrich W,Christ-Crain M,et al.Procalcitonin for guidance of antibiotic therapy[J].Expert Rev Anti Infect Ther,2010,8(5):575-587.
[5]Kafkas N,Venetsanou K,Patsilinakos S,et al.Procalcitonin in acute myocardial infarction[J].Acute Card Care,2008,10(1):30-36.
[6]Senturk T,Cordan J,Baran I,et al.Procalcitonin in patients with acute coronary syndrome:correlation with high-sensitive C-reactive protein, prognosis and severity of coronary artery disease[J].Acta Cardiol,2007,62(2):135-141.
[7]Picariello C,Lazzeri C,Chiostri M,et al.Procalcitonin in patients with acute coronary syndromes and cardiogenic shock submitted to percutaneous coronary intervention[J].Intern Emerg Med,2009,4(5):403-408.
[8]Bektas F,Soyuncu S,Gunduz I,et al.The value of procalcitonin,a novel inflammatory marker, in the diagnosis of myocardial infarction and evaluation of acute coronary syndrome patients[J].J Emerg Med,2011,41(5):524-530.
[9]Ataoglu HE,Yilmaz F,Uzunhasan I,et al.Procalcitonin:a novel cardiac marker with prognostic value in acute coronary syndrome[J].J Int Med Res,2010,38(1):52-61.
[10]Picariello C,Lazzeri C,Attanà P,et al.The impact of admission procalcitonin on prognosis in acute coronary syndromes:a pilot study[J].Biomarkers,2012,17(1):56-61.
[11]Sinning CR,Sinning JM,Schulz A,et al.Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease[J].Circ J,2011,75(5):1184-1191.
[12]Schiopu A,Hedblad B,Engstrm G,et al.Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study[J].J Intern Med,2012,272(5):484-491.

备注/Memo

备注/Memo:
收稿日期：2013-07-16.
通讯作者：刘梅林，主任医师，主要从事冠心病、血脂异常研究 Email：meilinliu@hotmail.com
作者简介：何晓全，住院医师，硕士生Email：heart_hexq@163.com
更新日期/Last Update: 2014-01-16